in an appropriate way to be most effective. One of the key elements in this regard is to provide an appropriate bridge between Pharmacoeconomics too as a science and Pharmacoeconomics as a policy and management tool. Pharmacoeconomics as a science focuses on the methodological points,which should be considered in order to have a valid and reliable analysis. It could focus on subjects such as: points to be considered in measuring effectiveness, pitfalls in the inclusion of costs, the reasons and the size of discounts in economic evaluations and so on. Pharmacoeconomics as a policy and management tool should concern more about selecting topics, persons or organizations which should perform economic evaluations; organizations which should be taken for the responsibility of applying the results of Pharmacoeconomics studies, methods for applying its results effectively, the level of cost effectiveness threshold, scale of fairness and acceptability, and so forth.
Requesting for Pharmacoeconomics the studies in Iran is being increased in recent years; mainly in response to the shortage of financial resources. It is clear that Pharmacoeconomics is going to play a more important role in pharmaceutical policy in the country in near future. While this could be considered as a step forward to the application of Pharmacoeconomics in pharmaceutical system, pharmaceutical authorities need to clarify the essential factors which could have an effective and acceptable role in Pharmacoeconomics studies in the pharmaceutical system.
At the time being, food and drug organisation, health department, and health insurance organizations are asking for economic evaluation analysis separately and without any systematic cooperation. This could increase inefficiency itself. Establishment of a systematic connection between various departments, which are customer of economic evaluation studies, is an important strategy to avoid duplication and unnecessary expenses.
Running economic evaluations is not costless itself. It is important to clarify who is responsible for the provision of financial support for such studies; and who would be benefited more from implementation of economic evaluation results in the Pharmaceutical system.
The last but not least point to consider is that, although the application of Pharmacoeconomics in designing policy may help to increase the efficiency of the system, it does not necessarily mean that the result would be a reduction in pharmaceutical expenditures. On the contrary, the results in some countries, like England and Wales, have shown that their pharmaceutical expenditures have also increased after development of National Institute for Health and Clinical Excellence (NICE) in 1999. Nevertheless, this may result in increasing the efficiency of the healthcare services, beside the provision of better health care services to the population. This reality could help us to understand that Pharmacoeconomics is not the answer of all challenges and issues in pharmaceutical policy. It could help decision makers to use their limited resources more efficiently if, and only if, it is brought about to practice appropriately.
In summary, Pharmacoeconomics in Iran, and also in other countries, could help policy makers to better design and drive their policy objectives more efficiently. But it is necessary to clarify, in advance, the expectations from applying Pharmacoeconomics, department to be in charge of applying the results of Pharmacoeconomics studies, values and standards to be considered in doing such studies, financial resources for performing and implementing its results, and its potential impact on various parts of pharmaceutical system including patients, pharmaceutical industry, and health insurance organizations. Clariflying these point will assist pharmaceutical policy makers to benefit from pharmacoeconomic more effectively. 
